CDK4 and neoplasm: Based on where each of these two classes of drugs works during the cell cycle, we hypothesize that two potential dosing schedules may produce enhanced cell killing effects: 1) initial exposure of cycling tumor cells to a CDK4/6 inhibitor synchronizes cells at the G1 phase.